{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:51:54Z","timestamp":1794667914063,"version":"4.9.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.annonc.2026.01.006","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:42:07Z","timestamp":1768894927000},"page":"777-786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial"],"prefix":"10.1016","volume":"37","author":[{"given":"R.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6359-8241","authenticated-orcid":false,"given":"Z.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.P.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4467-6021","authenticated-orcid":false,"given":"J.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2026.01.006_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.annonc.2026.01.006_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.21147\/j.issn.1000-9604.2020.06.03","article-title":"Gastric cancer: epidemiology, risk factors and prevention strategies","volume":"32","author":"Yang","year":"2020","journal-title":"Chin J Cancer Res"},{"issue":"10418","key":"10.1016\/j.annonc.2026.01.006_bib3","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.annonc.2026.01.006_bib4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1056\/NEJMoa2503119","article-title":"Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer","volume":"393","author":"Shitara","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.01.006_bib5","article-title":"Trends of gastric cancer burdens attributable to risk factors in China from 2000 to 2050","volume":"44","author":"He","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"issue":"8","key":"10.1016\/j.annonc.2026.01.006_bib6","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00432-014-1900-3","article-title":"HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison","volume":"141","author":"Koopman","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9742","key":"10.1016\/j.annonc.2026.01.006_bib7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.annonc.2026.01.006_bib8","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN \u2013 a randomized, phase III study","volume":"32","author":"Satoh","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.006_bib9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","article-title":"Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study","volume":"18","author":"Thuss-Patience","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.01.006_bib10","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","article-title":"Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study","volume":"19","author":"Tabernero","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2026.01.006_bib11","article-title":"1425P Efficacy and safety of KN026 in combination with chemotherapy in patients (pts) with unresectable or metastatic HER2 positive gastric or gastroesophageal cancers (GC\/GEJC) after first-line treatment with a trastuzumab-containing regimen","volume":"35","author":"Xu","year":"2024","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.annonc.2026.01.006_bib12","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.annonc.2026.01.006_bib13","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","article-title":"Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone","volume":"30","author":"Kang","year":"2012","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.annonc.2026.01.006_bib14","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.19.03077","article-title":"Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study)","volume":"38","author":"Makiyama","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.01.006_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","article-title":"Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)","volume":"22","author":"Seo","year":"2019","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.annonc.2026.01.006_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2018.09.024","article-title":"Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)","volume":"105","author":"Saeki","year":"2018","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2026.01.006_bib17","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/gutjnl-2018-316522","article-title":"Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer","volume":"68","author":"Wang","year":"2019","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.006_bib18","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-17-2781","article-title":"Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study","volume":"24","author":"Pietrantonio","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.annonc.2026.01.006_bib19","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"issue":"31","key":"10.1016\/j.annonc.2026.01.006_bib20","doi-asserted-by":"crossref","first-page":"51037","DOI":"10.18632\/oncotarget.17558","article-title":"Structural basis of a novel heterodimeric Fc for bispecific antibody production","volume":"8","author":"Wei","year":"2017","journal-title":"Oncotarget"},{"issue":"suppl 13","key":"10.1016\/j.annonc.2026.01.006_bib21","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1158\/1538-7445.AM2021-1032","article-title":"Abstract 1032: super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action","volume":"81","author":"Dixit","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.006_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","article-title":"A biparatopic HER2-targeting antibody\u2013drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy","volume":"29","author":"Li","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.006_bib23","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.annonc.2026.01.006_bib24","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.01.006_bib25","article-title":"CLARITY-Gastric 01: a randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC\/GEJC)","volume":"43","author":"Janjigian","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2026.01.006_bib26","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S1470-2045(25)00287-6","article-title":"Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study","volume":"26","author":"Elimova","year":"2025","journal-title":"Lancet Oncol"},{"issue":"suppl 3","key":"10.1016\/j.annonc.2026.01.006_bib27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO.2021.39.3_suppl.164","article-title":"Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): results from a phase I study","volume":"39","author":"Meric-Bernstam","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.01.006_bib28","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"29","key":"10.1016\/j.annonc.2026.01.006_bib29","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.2217\/fon-2022-0595","article-title":"HERIZON-GEA-01: zanidatamab + chemo \u00b1 tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma","volume":"18","author":"Tabernero","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.annonc.2026.01.006_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.LBA285","article-title":"Zanidatamab + chemotherapy (CT) \u00b1 tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): primary analysis from HERIZON-GEA-01","volume":"44","author":"Elimova","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.01.006_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.10.004","article-title":"KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer","volume":"178","author":"Xu","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2026.01.006_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101795","article-title":"Treatment-related adverse events associated with HER2-targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"55","author":"Fu","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.annonc.2026.01.006_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.40336","article-title":"Cardiotoxic effects of antibody drug conjugates vs standard chemotherapy in ERBB2-positive advanced breast cancer: a systematic review and meta-analysis","volume":"8","author":"Seth","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426000153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426000153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:29:07Z","timestamp":1779413347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426000153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0923753426000153"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.01.006","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}